# Q3-2026 Launch Readiness Verification (June 30–July 1, 2026)
## Pre-Launch Checklist & Execution Framework

**Assessment Date:** June 30, 2026  
**Launch Date:** July 1, 2026  
**Status:** READY FOR LAUNCH ✅

---

## Executive Summary

All infrastructure, stakeholder alignment, and resource commitments are in place for Q3-2026 launch on July 1, 2026. Five parallel initiatives (FMEA, EHR Integration, Observability, FDA Readiness, Dependency Audit) are poised to begin simultaneously with comprehensive planning, stakeholder buy-in, and risk mitigation in place.

**Critical Success Factors:**
1. ✅ All 5 Q3 initiative plans finalized and committed
2. ✅ Stakeholder resource commitments secured
3. ✅ Infrastructure and dependencies ready
4. ✅ Risk assessment and mitigation strategies documented
5. ✅ August 21 FDA decision vote scheduled and confirmed
6. ✅ Parallel execution timeline validated

---

## Infrastructure Readiness Checklist

### Observability & Monitoring (Q3-3 Initiative)

**Grafana Stack**
- [x] Grafana instance provisioned (production environment)
- [x] Admin access configured (Platform Eng team)
- [x] OpenTelemetry collector deployed and tested
- [x] OTLP ingestion endpoint verified (port 4317)
- [x] Tempo instance staging (scheduled deployment Jul 8)
- [x] Sample-based tracing configuration templates prepared
  - 100% error rate sampling ✅
  - 1% success rate sampling ✅
  - 10% high-latency (>500ms) sampling ✅
- [x] Service dependency graph dashboard template created
- [x] Trace detail dashboard template created
- [x] Alerting rules for trace pipeline health configured

**Readiness:** ✅ READY (Tempo deploy Jul 8 is on critical path)

---

### EHR Integration Environment (Q3-2 Initiative)

**Sandbox Access**
- [x] Epic sandbox: Credentials issued Jun 28; test patient loaded
  - Endpoint: https://epic-sandbox.test.com/api/fhir/r4
  - Auth: OAuth 2.0 client credentials (client_id: xxx, scope: patient/*.read)
  - Test patient: ID 12345 (pediatric growth data)
- [x] Cerner sandbox: Credentials issued Jun 29; test data loaded
  - Endpoint: https://cerner-sandbox.test.com/fhir/r4
  - Auth: OAuth 2.0 + SMART on FHIR
  - Test patient: ID 67890 (neonatal growth data)
- [x] FHIR library dependencies validated
  - fhir-client (v0.9.1) ✅
  - fhir-models (US Core 6.1) ✅
  - Hl7.Fhir.R4 (v4.0.1) ✅

**Data Mapping Templates**
- [x] Patient resource mapping (FHIR ↔ internal model) drafted
- [x] Observation resource mapping (growth metrics) drafted
- [x] DocumentReference mapping (clinical notes) drafted
- [x] DiagnosticReport mapping (assessment results) drafted
- [x] Encounter resource mapping (clinical encounters) drafted

**Readiness:** ✅ READY (Sandbox testing begins Jul 1)

---

### Risk Management Framework (Q3-1 Initiative)

**FMEA Workshop Materials**
- [x] Workshop invitation sent to stakeholders (Compliance Officer, Eng Lead, Product Manager, Clinical Advisor)
- [x] Workshop scheduled: Jul 8, 2026, 10 AM UTC (2 hours)
- [x] Agenda prepared (risk identification, scoring, mitigation)
- [x] Hazard mode brainstorm template prepared
- [x] Risk scoring matrix (severity × occurrence × detectability) prepared
- [x] Mitigation template prepared (design controls, verification evidence)
- [x] FHIR spreadsheet template created (18–25 hazard modes)
- [x] ISO 14971 process documentation template prepared

**Quarterly Review Schedule**
- [x] Q3 Review scheduled: Aug 15, 2026 (post-FMEA)
- [x] Q4 Review scheduled: Nov 15, 2026
- [x] Q1 2027 Review scheduled: Feb 15, 2027
- [x] Calendar invites sent to stakeholders

**Readiness:** ✅ READY (Workshop Jul 8 on critical path for Q3-4 FDA assessment)

---

### FDA Premarket Decision Framework (Q3-4 Initiative)

**Decision Vote Preparation**
- [x] Decision date locked: August 21, 2026 at 2 PM UTC
- [x] Decision committee confirmed (4 attendees: CEO, CFO, CTO, Compliance Officer)
- [x] Meeting room reserved (Zoom + conference room backup)
- [x] Assessment criteria finalized:
  - Technical: IEC 62304 ≥95%, SBOM/VEX, SLSA v1 provenance, cybersecurity NIST SP 800-218, 21 CFR Part 11
  - Regulatory: Device classification, QMS ISO 13485, labeling
  - Business: 2.5+ FTE resource commitment for premarket pathway
- [x] GO/NO-GO decision matrix prepared
- [x] Year 3 roadmap scenarios drafted (Device vs. Non-Device)

**Assessment Plan**
- [x] Technical review phase 1: Jul 1–15 (IEC 62304 traceability assessment)
- [x] Technical review phase 2: Jul 15–Aug 1 (SBOM/VEX analysis, provenance verification)
- [x] Cybersecurity assessment: Aug 1–10 (SSDF v1.1 scoring)
- [x] Regulatory & legal review: Aug 10–15 (device classification, QMS gaps)
- [x] Final business case: Aug 15–20 (resource commitment confirmation)
- [x] Decision vote: Aug 21 at 2 PM UTC (formal GO/NO-GO decision)

**Readiness:** ✅ READY (Critical path assessment begins Jul 1)

---

### Dependency Audit Framework (Q3-5 Initiative)

**Dependency Inventory Tools**
- [x] SBOM generation tools configured (syft, cyclonedx)
- [x] Dependency classification matrix template prepared (Tier 1/2/3)
- [x] Risk assessment criteria finalized
- [x] Policy template created (policies/dependencies.md)
- [x] Target repos identified:
  - PedNeoSim.jl (Julia package)
  - pediatric-cds (Python package)
  - audit-service (Go microservice)

**Readiness:** ✅ READY (Scheduled to start Sep 1, post-FDA decision)

---

## Stakeholder Alignment Verification

### Executive Steering Committee (CEO, CFO, CTO, Compliance Officer)

**Status:** ✅ ALIGNED (Jun 28 meeting)

**Confirmed Commitments:**
- CEO: Decision vote attendee (Aug 21); strategic oversight
- CFO: Decision vote attendee (Aug 21); resource allocation review
- CTO: Decision vote attendee (Aug 21); technical readiness verification
- Compliance Officer (Timothy H.): Q3-1 owner (30 hours), Q3-4 lead (10 hours), Q3-5 owner (8 hours)

**Resource Allocation Approved:**
- Q3-1 (FMEA): 10 hours (Timothy H.)
- Q3-4 (FDA): 12 hours (Timothy H.)
- Q3-5 (Dependency Audit): 8 hours (Timothy H.)
- Q3-2 (EHR Integration): 22 hours (Engineering Team)
- Q3-3 (Observability): 18 hours (Platform Engineering)
- Q3-4 (FDA): 2 hours executive decision (4 people × 0.5 hour = 2 hours)
- **Total:** 74 hours allocated; within Q3 capability

**Q3 Kickoff:** Jul 1, 2026 at 10 AM UTC (1 hour; all stakeholders confirmed)

---

### Engineering Team (Eng Lead, Platform Eng Lead)

**Status:** ✅ ALIGNED (Jun 29 meeting)

**Confirmed Commitments:**
- Engineering Team: Q3-2 (EHR Integration, 22 hours), 6-week timeline
- Platform Engineering: Q3-3 (Observability, 18 hours), 5-week timeline
- Shared: Ongoing support for chaos testing (Q2-4 continuation, ~2 hours/week)

**Resource Details:**
- Q3-2 Lead: Engineering Team Lead
- Q3-2 Team: 2 engineers + 1 DevOps
- Q3-3 Lead: Platform Engineering Lead
- Q3-3 Team: 2 platform engineers

**Infrastructure Support:**
- Sandbox environment setup: Epic + Cerner (complete)
- Tempo deployment: Scheduled Jul 8
- OpenTelemetry instrumentation: Jul 8–Aug 1
- Chaos testing: Continuing weekly (Tue/Thu 3 AM UTC)

---

### Clinical & Product Leadership

**Status:** ✅ ALIGNED (Jun 28 meeting)

**Confirmed Commitments:**
- Clinical Advisor: FMEA workshop attendee (Jul 8); risk identification support
- Product Manager: FHIR mapping guidance (Q3-2); user acceptance criteria
- Product Support: Post-market surveillance operational (ongoing from Q2)

**Clinical Input:**
- EHR integration requirements: Bidirectional sync preferred, data consistency critical
- Chaos testing continuation: Accepted; Tuesday/Thursday 3 AM UTC window works for clinical schedule
- Post-market surveillance: Ready to receive adverse events; SLA <1 hour for critical events

---

### Platform & DevOps Teams

**Status:** ✅ ALIGNED (Jun 29 meeting)

**Confirmed Commitments:**
- DevOps Lead: Tempo deployment (Jul 8); infrastructure support
- Infrastructure: OpenTelemetry collector updates; service mesh instrumentation
- Database Team: Replica failover chaos testing; MTBF monitoring

**Operational Readiness:**
- Maintenance window schedule published ✅
- SLO dashboard updated with maintenance exclusion ✅
- Chaos testing feedback loop operational ✅
- Observability platform ready for Tempo integration ✅

---

## Risk Assessment & Mitigation

### Critical Risks (Block Launch if Not Mitigated)

**None identified.** All infrastructure, stakeholder alignment, and resource commitments are in place.

---

### High-Risk Items (Require Proactive Monitoring)

| Risk | Probability | Impact | Mitigation | Owner | Review Frequency |
|------|-------------|--------|-----------|-------|-----------------|
| FDA Decision Complexity | Medium (40%) | Strategic direction change | Technical readiness assessment Jul 1–15; engage FDA counsel Jul 15 | Timothy H. | Weekly |
| FHIR Integration Scope Creep | Medium (35%) | Schedule slip from 6 weeks | Design review checkpoint Jul 15; Epic sandbox testing Sep 1 | Eng Lead | Bi-weekly |
| Tempo Deployment Risk | Low (15%) | Production impact; trace data loss | Blue-green deployment strategy; 2-week buffer (Jul 8–22) | Platform Eng | Daily (deployment week) |
| EHR Sandbox Stability | Low (20%) | Integration test delays | Fallback sandbox credentials prepared; Cerner vendor support on-call | Eng Lead | Weekly |
| Resource Conflict (Vacation) | Low (25%) | Staffing gaps during Aug | Resource backup identified; cross-training initiated Jun 30 | Eng Lead | Weekly |

---

### Medium-Risk Items (Track & Document)

| Risk | Mitigation | Owner |
|------|-----------|-------|
| MTBF tracking accuracy in Q3 | Continue weekly chaos testing correlation analysis | Platform Eng |
| Post-market event processing volume | Monitor pilot event processing time; scale automation if needed | Timothy H. |
| Q3-4 legal/regulatory alignment | Schedule pre-FDA counsel consultation Jul 15 | Timothy H. |
| Q3-5 dependency audit findings | Identify non-compliant packages early (Sep 1); plan remediation | Timothy H. |

---

## Q3 Execution Timeline at a Glance

### July 2026 (Weeks 1–4)

**Jul 1 (Tuesday) — Q3 Launch Day**
- 10 AM UTC: Executive kickoff meeting (1 hour)
- All 5 initiatives officially begin
- Resource teams mobilized

**Jul 2 (Wednesday) — EHR Integration Kick-off**
- 10 AM UTC: Engineering Team + Clinical Advisor meeting (1 hour)
- FHIR mapping specification review
- Epic/Cerner sandbox testing begins

**Jul 8 (Tuesday) — FMEA Workshop + Tempo Deploy**
- 10 AM UTC: FMEA workshop (2 hours)
  - Risk identification (18–25 hazard modes)
  - Initial scoring
- Parallel: Tempo deployment (Platform Eng)
- Service mesh instrumentation planning

**Jul 15 (Tuesday) — Checkpoint 1**
- FMEA 50% documented ✅
- EHR mapping specification draft complete ✅
- Tempo deployed, instrumentation starting ✅
- FDA technical review phase 1 complete ✅
- Pre-FDA counsel consultation

**Jul 22 (Tuesday) — Checkpoint 2**
- FMEA complete ✅
- EHR implementation 50% complete
- Tempo instrumentation ongoing
- FDA technical review phase 2 starting

**Jul 28 (Monday) — FMEA Final**
- FMEA baseline frozen for input to FDA assessment
- Quarterly review schedule published
- Risk acceptance form signed

---

### August 2026 (Weeks 5–8)

**Aug 1 (Friday) — Mid-Execution Review**
- FMEA complete ✅
- EHR implementation 50% complete
- Tempo dashboard prototypes live
- FDA technical review phase 2 complete; cybersecurity assessment starts

**Aug 8 (Friday) — Checkpoint 3**
- EHR mapping specification complete
- Integration tests 50% complete
- FDA cybersecurity assessment ongoing
- Tempo production deployment complete

**Aug 15 (Friday) — Midpoint Review**
- EHR sandbox testing in progress; integration tests 80% complete ✅
- Observability dashboard live; sampling rules active ✅
- FDA regulatory + legal review complete; final business case compiled
- Pre-decision briefing with decision committee

**Aug 21 (Thursday, 2 PM UTC) — CRITICAL DECISION VOTE**
- FDA GO/NO-GO decision vote (formal decision committee meeting)
- **GO Outcome:** Proceed to premarket package; Y3 roadmap: FDA submission path
- **NO-GO Outcome:** Pivot to TEFCA/QHIN non-device platform; Y3 roadmap: Platform expansion
- Year 3 roadmap updated conditional on decision

**Aug 28 (Thursday) — Post-Decision Alignment**
- All initiatives updated based on decision
- Q3-5 (Dependency Audit) mobilized for Sep 1 start
- Year 3 team structure finalized

---

### September 2026 (Weeks 9–13)

**Sep 1 (Monday) — Dependency Audit Begins**
- Q3-5 official start
- Dependency inventory and classification begins
- Q3-2 (EHR) sandbox testing final phase
- Q3-3 (Observability) production validation

**Sep 14 (Sunday) — Dependency Audit Complete**
- Dependency inventory 100% classified ✅
- Risk assessment complete ✅
- Policy published ✅
- Remediation plan for non-compliant dependencies documented

**Sep 30 (Tuesday) — Q3 Closure**
- All 5 initiatives complete ✅
- Compliance score target 89/100 achieved ✅
- Q3-2026 review meeting scheduled (Oct 1)
- Year 3 roadmap finalized (conditional on Aug 21 decision)

---

## Launch Day (July 1) Execution Plan

### Pre-Launch (Jun 30)

- [x] All 5 initiative plans committed to git
- [x] Stakeholder alignment confirmed
- [x] Infrastructure readiness verified
- [x] Risk assessment documented
- [x] Resource allocations confirmed
- [x] Calendar invitations sent

### Launch Day — Jul 1, 2026

**08:00 UTC — Final Readiness Check**
- All systems online (Grafana, sandbox environments, FHIR libraries)
- Team members logged in and ready
- Communication channels active (#engineering, #compliance, #observability)

**10:00 UTC — Executive Kickoff Meeting (1 hour)**
- Attendees: CEO, CFO, CTO, Compliance Officer, Eng Lead, Platform Eng Lead
- Agenda:
  1. Q3 overview & timeline (10 min)
  2. Initiative deep-dives (20 min: 4 min per initiative)
  3. August 21 FDA decision preparation (10 min)
  4. Q&A and final questions (10 min)
  5. Formal authorization to proceed (5 min)
- Output: Executive sign-off; all teams mobilized

**11:00 UTC — Team Mobilization**

- **Engineering Team:** EHR Integration kickoff (async prep for Jul 2 meeting)
- **Platform Engineering:** Tempo deployment planning
- **Compliance Officer:** FMEA workshop final prep
- **All Teams:** Review respective initiative plans; confirm timeline understanding

**17:00 UTC — Day 1 Wrap-Up**
- Status update: All initiatives green for execution
- Slack announcement: "Q3-2026 LAUNCHED ✅ All systems go"
- Next checkpoints documented

---

## Success Criteria for Q3-2026

### Initiative-Level Success

| Initiative | Success Criteria |
|-----------|-----------------|
| Q3-1 (FMEA) | Baseline FMEA with 18–25 hazard modes; quarterly review cycle operational |
| Q3-2 (EHR) | FHIR mapping complete; 10+ integration tests passing; sandbox verified |
| Q3-3 (Observability) | Tempo deployed; service dependency dashboards live; tracing sampling active |
| Q3-4 (FDA) | Comprehensive readiness assessment complete; formal GO/NO-GO decision made |
| Q3-5 (Dependency) | 100% of dependencies classified; policy published; remediation plan documented |

### Compliance-Level Success

| Factor | Target | Measurement |
|--------|--------|-------------|
| Composite Score | 89/100 | Scorecard calculation from 6 factors |
| Supply Chain | 95% | SLSA/Provenance coverage (maintained from Q2) |
| Code Quality | 85% | Scorecard average (maintained from Q2) |
| Device Classification | 100% | Org repo classification (maintained from Q2) |
| Resilience | 35+ days | MTBF from chaos testing (target 35; Q2 achieved 34.7) |
| Post-Market | 80% | Event processing + policy (up from Q2: 70%) |
| Availability | 99.9% | SLO maintenance (maintained from Q2) |

---

## Contingency & Escalation

### If Risk Event Occurs

**Escalation Path:**
1. **Operational Issue:** Initiative lead → Platform Lead → CTO (daily standups)
2. **Resource Conflict:** Initiative lead → Eng Lead → CFO (resource reallocation)
3. **FDA Decision Impact:** Compliance Officer → CEO + CTO (executive alignment)
4. **Scope Creep:** Initiative lead → CTO (scope review gate)

**Contingency Plans Documented:**
- EHR sandbox unavailability: Fallback to Cerner sandbox only (1 week delay acceptable)
- Tempo deployment failure: Roll back to Jaeger ephemeral traces; retry deployment
- FMEA scope expansion: Defer non-critical modes to Q4 review; baseline remains frozen
- FDA assessment delay: Maintain Aug 21 decision date as hard stop; present partial readiness

---

## Approval & Sign-Off

**Q3-2026 Launch Approved By:**

- [x] **Timothy Hartzog** — Compliance Officer (Initiatives 1, 4, 5)
- [x] **Engineering Lead** — (Initiatives 2, 3)
- [x] **Executive Sponsor** — Strategic oversight (Initiative 4 decision gate)

**Approval Date:** June 30, 2026  
**Effective Start:** July 1, 2026  
**Target Completion:** September 30, 2026  
**Critical Decision Date:** August 21, 2026

---

## Launch Confirmation

**Status: ✅ READY FOR LAUNCH**

All infrastructure, stakeholder alignment, resource commitments, and risk mitigation are in place. Q3-2026 is approved to launch on July 1, 2026 with all 5 initiatives executing in parallel toward September 30 completion and 89/100 compliance target.

**July 1, 2026 at 10:00 UTC — EXECUTION BEGINS**

